Dr. Kim Kjøller: Precision Medicine and AI in Drug Development | Stories in Life Sciences

Drug development is being reshaped by AI, precision medicine, and a growing culture of collaboration across the life sciences. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Kim Kjøller, CEO of Union Therapeutics, to explore what that transformation looks like from inside a leading biotech company.Dr. Kjøller draws on decades of experience in Big Pharma to discuss how Union Therapeutics is advancing therapies for chronic diseases, why Denmark's collaborative biotech ecosystem has become a global model for life sciences innovation, and what it takes to bring a European biotech into the U.S. healthcare market.In this episode of Stories in Life Sciences, we cover:How AI is accelerating data-driven drug discovery and developmentUnion Therapeutics' approach to advancing therapies for chronic diseasesLessons from decades in Big Pharma applied to biotech innovationWhy Denmark's Life Science Cluster is a global model for collaborationThe challenges of entering the U.S. healthcare market as a European biotechThe growing role of precision medicine and prevention in patient careWho this is for: founders, investors, clinicians, and researchers in biotech, pharma R&D, precision medicine, and life sciences who want to understand how collaboration and AI are changing drug development.Guest: Dr. Kim Kjøller, CEO, Union Therapeutics www.uniontherapeutics.comhttps://www.linkedin.com/company/uniontherapeuticsHost:Christopher Wilson, Founder, MedAxis AIwww.medaxisai.org https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisaiFollow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.